scholarly journals Reviewing the Effects of Miltefosine and Suggesting It for the Treatment of Coronavirus Disease (COVID-19)

2020 ◽  
Vol 13 ◽  
pp. 117863372097748
Author(s):  
Alireza Latifi
Keyword(s):  
Treatment Options ◽  
Antiviral Effect ◽  
Functional System ◽  
Cancer Drug ◽  
Therapeutic Effects ◽  
Pathogenic Microorganisms ◽  
Free Living ◽  
Beneficial Effects ◽  
Anti Cancer ◽  
Free Living Amoeba

Objective: Miltefosine is an anti-cancer drug used to treat leishmaniasis and deadly opportunistic free-living amoeba and other deadly pathogenic microorganisms. Several studies have demonstrated its antiviral effect. In this study, we discuss the effectiveness of this drug on pathogenic microorganisms, and according to the functional system of the medicine, we present this drug as a therapeutic proposal to treat Coronavirus disease (COVID-19) Methods: A literature search was conducted in electronic databases, including Pubmed, Science Direct, Elsevier, and Google Scholar, and articles published from 2006 to 2020 (the last decade) were selected. The search keywords included Miltefosine, microorganism, pathogen, and treatment. Results: The studies indicated that Miltefosine had therapeutic effects on leishmaniasis and deadly opportunistic free-living amoeba and other deadly pathogenic microorganisms. Several studies have proven its antiviral effect. Conclusion: Owing to the beneficial effects of this drug on pathogenic and deadly microorganisms and antiviral effects, and due to the epidemic of Coronavirus and the lack of effective treatment and vaccine, this drug is recommended as one of the treatment options for this disease.

Medical cost of care by line of treatment (LoT) in Medicare Fee-for-Service (FFS) beneficiaries with KRAS-mutated metastatic non-small cell lung cancer (mNSCLC).

2020 ◽  
Vol 38 (29_suppl) ◽  
pp. 63-63
Author(s):  
Tara Matsuda ◽  
Aurelien Jamotte ◽  
Ann Xi ◽  
Barton Jones ◽  
Allison Petrilla ◽  
...  
Keyword(s):  
Medical Cost ◽  
Medical Management ◽  
Treatment Options ◽  
Medical Costs ◽  
Cost Of Care ◽  
Cancer Drug ◽  
Fee For Service ◽  
Kras Mutations ◽  
Real World Evidence ◽  
Anti Cancer

63 Background: While no targeted therapy is currently approved for patients with KRAS-mutated mNSCLC, new therapies are being developed for patients with KRAS p.G12C-mutated NSCLC. However, real-world evidence on cost of care in managing this population is currently lacking. This study addresses this gap by describing costs of mNSCLC patients with KRAS mutations, stratified by LoT and relative to exposure to a PD(L)1 inhibitor [PD(L)1i]. Methods: Medicare FFS claims (100% sample, Parts A/B) and the PROGNOS NSCLC Explorer dataset were linked to identify patients with mNSCLC, a positive KRAS biomarker test result, and anti-cancer treatment from July 2014 - June 2018. Patients were followed from date of metastasis and stratified by LoT and prior and current exposure to PD(L)1i. Mean total medical costs included all Medicare-covered Parts A/B costs. On treatment medical costs during each LoT were reported per patient per month (PPPM) and were categorized as anti-cancer drug costs or medical management costs (excluding anti-cancer drugs). Results: 438 beneficiaries met inclusion criteria: median age 75 years, 54% female, 91% white, 116 with G12C mutations. 1L patients receiving PD(L)1i had higher total medical costs ($14,331) than those not receiving PD(L)1i ($10,055). Total medical cost of care was similar between patients on 1L ($12,178) and 2L/3L ($12,042). Although total cost of care was similar among 2L/3L patients, irrespective of PD(L)1i exposure status, the medical management costs in patients who progressed after a PD(L)1i or had never received a PD(L)1i were almost twice the medical management costs of the PD(L)1i treated patients. Conclusions: This study demonstrates a high economic burden exists among Medicare patients with KRAS-mutated mNSCLC who have progressed after 1L therapy and for whom there are no targeted treatment options available. [Table: see text]

scholarly journals Clinical Effects of Topical Tacrolimus on Fox-Fordyce Disease

2015 ◽  
Vol 2015 ◽  
pp. 1-3 ◽  
Author(s):  
Hilal Kaya Erdoğan ◽  
Işıl Bulur ◽  
Zeliha Kaya
Keyword(s):  
Carbon Dioxide Laser ◽  
Treatment Options ◽  
Sweat Glands ◽  
Therapeutic Effects ◽  
Inflammatory Disorder ◽  
Clinical Effects ◽  
Apocrine Glands ◽  
Topical Tacrolimus ◽  
Beneficial Effects ◽  
Fractional Carbon Dioxide Laser

Fox-Fordyce Disease (FFD) is a rare, chronic, pruritic, inflammatory disorder of apocrine glands. It is characterized by dome-shaped, firm, discrete, skin-colored, and monomorphic perifollicular papules. The most common sites of involvement are axillae and anogenital and periareolar regions which are rich in apocrine sweat glands. Treatment is difficult. Topical, intralesional steroids, topical tretinoin, adapalene, clindamycin, benzoyl peroxide, oral contraceptives, isotretinoin, phototherapy, electrocauterisation, excision-liposuction and curettage, and fractional carbon dioxide laser are among the treatment options. In the literature, there are articles reporting beneficial effects of pimecrolimus in FFD. Nevertheless, there have not been any reports about the use of tacrolimus in FFD. We report two patients diagnosed with FFD by clinical and histopathologic examination and discussed therapeutic effects of topical tacrolimus on FFD in the light of literature.

Ursolic Acid in Cancer Treatment and Metastatic Chemoprevention: From Synthesized Derivatives to Nanoformulations in Preclinical Studies

2019 ◽  
Vol 19 (4) ◽  
pp. 245-256 ◽  
Author(s):  
Junjie Zou ◽  
Juanfang Lin ◽  
Chao Li ◽  
Ruirui Zhao ◽  
Lulu Fan ◽  
...  
Keyword(s):  
Ursolic Acid ◽  
Cancer Metastasis ◽  
Biological Activities ◽  
Inhibitory Effect ◽  
Cancer Drug ◽  
Therapeutic Effects ◽  
Candidate Drug ◽  
Wide Range ◽  
Anti Cancer ◽  
Tumor Growth And Metastasis

Background:Cancer metastasis has emerged as a major public health threat that causes majority of cancer fatalities. Traditional chemotherapeutics have been effective in the past but suffer from low therapeutic efficiency and harmful side-effects. Recently, it has been reported ursolic acid (UA), one of the naturally abundant pentacyclic triterpenes, possesses a wide range of biological activities including anti-inflammatory, anti-atherosclerotic, and anti-cancer properties. More importantly, UA has the features of low toxicity, liver protection and the potential of anti-cancer metastasis.Objective:This article aimed at reviewing the great potential of UA used as a candidate drug in the field of cancer therapy relating to suppression of tumor initiation, progression and metastasis.Methods:Selective searches were conducted in Pubmed, Google Scholar and Web of Science using the keywords and subheadings from database inception to December 2017. Systemic reviews are summarized here.Results:UA has exhibited chemopreventive and therapeutic effects of cancer mainly through inducing apoptosis, inhibiting cell proliferation, preventing tumor angiogenesis and metastatic. UA nanoformulations could enhance the solubility and bioavailability of UA as well as exhibit better inhibitory effect on tumor growth and metastasis.Conclusion:The information presented in this article can provide useful references for further studies on making UA a promising anti-cancer drug, especially as a prophylactic metastatic agent for clinical applications.

scholarly journals Overexpression of a G-protein coupled receptor-like gene affects encystment of Acanthamoeba castellanii

2021 ◽  
Author(s):  
Steven Rolland ◽  
Anne Mercier ◽  
Luce Mengue ◽  
Yann Hechard ◽  
Ascel Samba-Louaka
Keyword(s):  
G Protein ◽  
Early Phase ◽  
Acanthamoeba Castellanii ◽  
Pathogenic Microorganisms ◽  
G Protein Coupled Receptor ◽  
Free Living ◽  
Vegetative Form ◽  
Free Living Amoeba ◽  
G Protein Coupled

Acanthamoeba castellanii is an amphizoic free-living amoeba as it can be found in humans and in the environment. This amoeba represents an important reservoir of pathogenic microorganisms. Persistence of A. castellanii in the environment or in humans is allowed by the ability of the vegetative form to differentiate under cysts when surrounding conditions are unfavorable. In this study, we investigate the role of the ACA1_383450 gene during encystment of A. castellanii. This gene encodes a putative G-protein coupled receptor, which shares homology with human GPR107 and murine GPR108. Expression of the ACA1_383450 gene is transiently repressed at the early phase of encystment and its overexpression affects encystment of A. castellanii. This study reveals a new Acanthamoeba gene which could affect the encystment process.

Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes

Xenobiotica ◽  
2009 ◽  
Vol 00 (00) ◽  
pp. 090901052053001-8
Author(s):  
K. Murai ◽  
H. Yamazaki ◽  
K. Nakagawa ◽  
R. Kawai ◽  
T. Kamataki
Keyword(s):  
Cytochrome P450 ◽  
Human Liver ◽  
Liver Microsomes ◽  
Human Liver Microsomes ◽  
Cancer Drug ◽  
Anti Cancer ◽  
Cytochrome P450 2A6

Psychogenic Mass Syndrome in Anti-Cancer Drug Exposure

2010 ◽  
Author(s):  
N. Magnavita ◽  
I. lavicoli ◽  
V. Leso ◽  
A. Bergamaschi
Keyword(s):  
Drug Exposure ◽  
Cancer Drug ◽  
Anti Cancer

Balamuthia mandrillaris: A Rare Free-Living Amoeba

2015 ◽  
Vol 2 (1) ◽  
Author(s):  
Jessica Chan ◽  
Mirella Mircescu ◽  
Pratik Shah ◽  
Andrew Liguori ◽  
Aaron Shmookler
Keyword(s):  
Free Living ◽  
Balamuthia Mandrillaris ◽  
Free Living Amoeba

A fatal case of meningoencephalitis due to a free-living amoeba of uncertain identity—probably acanthamoeba SP

Pathology ◽  
1981 ◽  
Vol 13 (1) ◽  
pp. 51-68 ◽  
Author(s):  
Rodney F. Carter ◽  
G.J. Cullity ◽  
V.J. Ojeda ◽  
P. Silberstein ◽  
E. Willaert
Keyword(s):  
Fatal Case ◽  
Free Living ◽  
Free Living Amoeba
Sign in / Sign up

Export Citation Format

Share Document